We are thrilled to announce that MacroGenics has successfully raised $40 million in a recent funding round aimed at accelerating our mission to develop groundbreaking therapies for cancer patients. As a leader in the discovery and development of innovative medicines utilizing next-generation antibody-based technologies, MacroGenics is committed to advancing the treatment landscape for cancer with a robust pipeline of product candidates. This substantial funding will not only enhance our research and development efforts but also enable us to expand our partnerships with leading pharmaceutical and biotechnology companies globally, fostering collaboration to bring forth transformative solutions for patients in need. Our dedicated team of over 300 professionals embodies our belief that the most valuable asset of a company is its people; we continuously invest in their growth and learning opportunities. The recent investment is a testament to the confidence that our investors have in our innovative approaches and our corporate culture, which promotes an atmosphere of open communication, teamwork, and innovation. As we embark on this pivotal journey, we remain committed to empowering our employees, ensuring they understand how integral their contributions are to our collective success. Together, we look forward to making meaningful strides in the fight against cancer, and we鈥檙e excited for the opportunities that lie ahead as we leverage this new capital to realize our vision for a healthier future.








